Claims for Patent: 6,143,727

Summary for Patent: 6,143,727

Title:	Specific expression vectors and methods of use
Abstract:	Gene therapy by using specific expression vectors within the epidermis or epidermal cells. These vectors incorporate regulatory sequences of tissue and differentiation-specific genes.
Inventor(s):	Roop; Dennis R. (Houston, TX), Rothnagel; Joseph A. (Houston, TX), Greenhalgh; David A. (Houston, TX)
Assignee:	Baylor College of Medicine (Houston, TX)
Application Number:	08/458,240
Patent Claims:	1. A method of treating skin cancer in a mammal comprising administering a loricrin or K6 keratin expression vector at or directly around the site of a skin cancer cell, wherein said vector comprises in operable association: a nucleic acid sequence encoding a wild-type p53 protein; a 5' flanking region from a mammalian gene including necessary sequences for expression of said nucleic acid sequence; a 3' flanking region from a mammalian loricrin or a mammalian keratin K6 gene which regulates expression predominantly in epidermal tissue; and a linker connecting said 5' flanking region to said nucleic acid sequence, said linker having a position in which said nucleic acid sequence is inserted, wherein expression of said p53 protein by said skin cancer cell results in inhibition of the cell's proliferation. 2. The method of claim 1, wherein said 5' flanking region and said 3' flanking region are from a loricrin gene. 3. The method of claim 1, wherein said 5' flanking region and said 3'flanking region are from a K6 keratin gene. 4. The method of claim 1, wherein said 5' flanking region includes a promoter, a TATA box, a CAP site and a first intron and intron/exon boundary in appropriate relationship for expression of said nucleic acid sequence. 5. The method of claim 4, wherein said 5' flanking region is approximately 1.5 kb, said intron is approximately 1.1 kb and said 3'flanking sequence is approximately 2.1 kb from a loricrin gene. 6. The method of claim 4, wherein said 5' flanking region is approximately 8.0 kb, said intron is approximately 0.56 kb and said 3' flanking sequence is approximately 1.2 kb from a K6 keratin gene. 7. The method of claim 4, wherein said 5' flanking region comprises a unique 5' Xho I site up to nucleotide 360 of Sequence ID No. 3; said intron and intron/exon boundary comprises nucleotides 928 to 1494 of Sequence ID No. 3; said 3' flanking region comprises from nucleotide 4740 of Sequence ID No. 3 a unique 3' Xho I site; and said linker is inserted between nucleotides 1504 to 1509 of Sequence ID No. 3. 8. The method of claim 4, wherein said 5' flanking region comprises nucleotides 1 to 1540 of Sequence ID No. 1; said intron and intron/exon boundary comprises nucleotides 1587 to 1679 of Sequence ID No. 1; said 3' flanking region comprises nucleotides 4384 to 6530 of Sequence ID No. 1; and said linker is inserted at the unique Cla I site at nucleotides 2700 to 2705 of Sequence ID No. 2. 9. The method of claim 1, wherein said skin cancer cell is a mammalian epidermal cell or a mammalian squamous epithelial cell. 10. The method of claim 9, wherein said 5' flanking region and said 3' flanking region are from a loricrin gene. 11. The method of claim 9, wherein said 5' flanking region and said 3' flanking region are from a K6 keratin gene. 12. The method of claim 9, wherein said skin cancer cell is a squamous epithelial cell selected from the group consisting of epidermis, oral mucosa, esophageal, vaginal, tracheal or corneal epithelia. 13. The method of claim 9, wherein said skin cancer cell is an epidermal cell.

Details for Patent 6,143,727

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-11-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-11-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-11-07